University of Illinois at Chicago
Announcement of an Exempt Purchase
Vendor: Profounda, Incorporated, Orlando, FL
Amount: An estimated $600,000
An estimated start date of 1/15/2020 through 6/30/2022
The University award process may be delayed up to thirty days as this award goes through a state approval process.
First published Thursday, January 9, 2020
The University awarded a contract for Impavido capsules.
Impavido capsules are an FDA-approved treatment for mucosal and visceral Leishmaniasis.
This purchase is exempt from the usual selection processes of the Procurement Code because the procurement expenditure is for medical supplies or medical services necessary for the delivery of care and treatment at medical, dental, or veterinary teaching facilities utilized by SIU or U of I (30 ILCS 500 / 1-13(b-5)) The purchase of Impavido allows UI Health to treat Leishmaniasis disease. In its mucosal form, the disease is disabling and mutilating. In its visceral form, the disease affects the spleen, liver, bone marrow, and lymph nodes and can be fatal.
For instructions on how to obtain a comprehensive purchase description, disclosure or contract forms, contact:
The State of Illinois has a policy to encourage prospective vendors to hire
qualified veterans, minorities, females, persons with disabilities and ex-offenders.